Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338312 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL190173 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL2896341 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL1991179 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL1991177 | 0.95 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL14398395 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL25980668 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL31336384 | 0.94 | HPGD (0.47) | HSD17B10SMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL9381153 | 0.90 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2ALDH1A1NPC1MEN1 | |
| SCHEMBL2030521 | 0.90 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2ALDH1A1HPGDCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462622-B | Preparation method of N-Boc-L-prolyl | 上海药坦药物研究开发有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-116462622-A | Preparation method of N-Boc-L-prolyl | 上海药坦药物研究开发有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-114920683-A | Preparation method of Boc-prolinaldehyde and (R, E) - (1-methylpyrrolidine-2-yl) acrylic acid | 苏州富士莱医药股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114602555-A | Preparation method and application of chitosan Schiff base immobilized copper material | 湖北工程学院 | 2022-06-10 | — | — | CN | claimed |
| JP-5025125-A | — | — | None | — | — | JP | disclosed |
| CN-116829557-B | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-5095006-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0468469-A2 | Proline derivatives | Japan Tobacco Inc. (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0412350-A2 | Renininhibitors, procedure for their preparation and use as medicaments | BAYER AG (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0384341-A2 | New proline derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1990-08-29 | — | — | EP | disclosed |
| WO-1990004588-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-05-03 | — | — | WO | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
| EP-0207420-A2 | Pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HSD17B10 1332/4885SMN1; SMN2 4141/4885ALDH1A1 1299/4885 |
| US-20260078116-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, MCL1 | HSD17B10 4362/4885SMN1; SMN2 958/4885ALDH1A1 3887/4885 |
| US-20260109696-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | KRAS, MYC, NRAS | HSD17B10 3043/4885SMN1; SMN2 1323/4885ALDH1A1 3241/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | HSD17B10 3355/4885SMN1; SMN2 4051/4885ALDH1A1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.